Shared Management for the Treatment of Psoriatic Disease

Psoriatic arthritis (PsA) affects about 1 in 3 people with psoriasis, and early recognition, diagnosis, and treatment can potentially prevent and/or limit irreversible joint damage.[1] However, research has shown that there is a high prevalence of undiagnosed PsA in patients with psoriasis. [2]

Recognizing the importance of clinicians staying current on diagnosing and managing PsA, the National Psoriasis Foundation and Evan Siegel, M.D., Elaine Husni, M.D., and Joseph F. Merola, M.D., held a Shared Management of Psoriatic Disease Roundtable. This roundtable was divided into 4 modules:

Module 1: Psoriatic Arthritis: Pathophysiology, Prevalence, Psychosocial Impact, and Care

• Overview of PsA prevalence and presentation
• Psoriasis/PsA as a systemic disease
• Impact on the patient
• ACR/NPF guidelines for treatment of psoriatic arthritis

Module 2: Comorbidities

• Overview of comorbidities associated with psoriasis, including PsA
• Informing patients about comorbidities; partnering with patients
• Emphasis on screening recommendations and screening tools
• Case example and discussion

Module 3: Shared Management

• Collaborative care with a multidisciplinary approach – not just dermatology/rheumatology collaboration, but also working with GI, Cardiology, etc.
• When to refer – particularly important for the primary care audience
• Case example and discussion

Module 4: Case Discussions

• Roundtable discussion on several real psoriasis and PsA cases

Due the importance of this topic, not only for health care providers but for patients who are at risk, this Roundtable is freely available as enduring, evidence-based video CME series. Each video is between 20-30 minutes and the entire series is accredited for 1.5 AMA PRA Category 1 CreditsTM.